NAD+ Research — What the Lab Data Actually Says
NAD+ drops 50% from age 20 to 50. The published trials on what restores it.
NAD+ — nicotinamide adenine dinucleotide — is the cofactor that mitochondrial energy production, sirtuin activity, and PARP-mediated DNA repair all run on. Serum NAD+ falls roughly 50 percent between age 20 and 50, with another 20 percent drop by age 65. The fall is one of the most replicable biological correlates of aging in the published literature.
The intervention literature has converged on two restoration strategies. NMN (β-nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two precursors that reliably raise serum NAD+ in human trials. The supportive doses are 250–1,000 mg daily depending on bodyweight and target. The Sinclair lab's work, the Yoshino et al. 2021 metabolic trial, and the Martens et al. 2018 vascular function trial all sit in this dose range. Resveratrol's role is mechanistically distinct — it activates SIRT1, the enzyme whose substrate is the NAD+ the precursors restore. Co-formulation is dose-multiplicative, not additive.
What follows: the deep-dives, the supplements built on the literature, and the working researchers whose ongoing publications drive what we update each quarter.
Research Library — full deep-dives on this topic
-
The NMN-Resveratrol Stack: 7 Reasons Bryan Johnson Takes Both
Mechanism breakdown — why SIRT1 activation and NAD+ restoration are dose-multiplicative. -
The Cellular Powerhouse Protocol — Mitochondrial & NAD+ Guide
The full 60-day NAD+ restoration protocol with biomarker checkpoints. -
Why VO2 Max Predicts Lifespan Better Than Smoking History
VO2 max is the most-cited biomarker for mitochondrial capacity — and NAD+ is the substrate. -
The Multivitamin Myth: Why 27 Years of RCTs Show No Lifespan Benefit
Why the multivitamin format fails — and why targeted single-active NAD+ precursors work.
The supplements built on this research
NMN + Resveratrol Complex 500mg →
β-NMN at 500 mg + trans-resveratrol at 250 mg — the dose ranges used in the Yoshino 2021 metabolic trial and the Sinclair lab's published work.
Join the readers tracking what the longevity researchers actually do.
Weekly research feed — what changed, what replicated, what the labs are publishing right now.
Join the Research Feed →Go deeper
The working researchers to follow on NAD+ are David Sinclair (Harvard Medical School), Shin-ichiro Imai (Washington University in St. Louis), Eric Verdin (Buck Institute), and Charles Brenner (City of Hope). Their published work is what we update against quarterly. See the full Cellular Powerhouse Protocol for the 60-day restoration playbook.
First time here? Read who this is for — what we believe, what we don't, and whether the protocol matches how you actually want to age.